CREEGH PHARMACEUTICALS INC

Pittsburgh, PA · Founded 2018 · CIK 0001817450 · Biotech · Private

Nitro fatty acid compounds (CP-8) that inhibit RAD51-mediated homologous recombination DNA repair to sensitize triple-negative breast cancer to PARP inhibitors and radiation

Grants
$797K
2 awards
Sector median: 1
Raised
$500K
1 Form D · Jul 2020
75 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$500,000
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Synergize a novel homologous recombination inhibitor with DNA damagingagents in TNBC$398,728
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Synergize a novel homologous recombination inhibitor with DNA damagingagents in TNBC$398,728
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2230Inflection Medicine——
2231Tenvie——
2232MITO-BIOTHERAPEUTICS, INC.——
2233CREEGH PHARMACEUTICALS INC—$500K
2234Advac Therapeutic LLC——
2235I Peace, Inc.—$47M
2236L.E.A.F. Pharmaceuticals LLC—$40M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Bruce FreemanDirector · Executive Officer
  • Francisco SchopferDirector · Executive Officer
  • Joshua TarnoffDirector
  • Margaret TarpeyExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.